Improvement of Ischemic Myocardial Dysfunction by Nisoldipine

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 1994 May 1

PMID 7947379

Citations 1

Authors

K Saida

M Umeda

A Itakura

Affiliations

Soon will be listed here.

Abstract

We examined the cardioprotective effect of nisoldipine against myocardial dysfunction during ischemia and reperfusion in Langendorff perfused rabbit hearts. Nisoldipine was administered to the hearts before 60 minutes of global ischemia. This agent inhibited the increase of end-diastolic pressure during ischemia and also improved the recovery of left ventricular developed pressure and coronary flow during reperfusion in a concentration-dependent manner. The maximal cardioprotective effect was observed in 10(-8) M nisoldipine. The beneficial effect was associated with an increase of coronary flow during reperfusion. Therefore, both the nisoldipine-increased coronary flow during reperfusion and the inhibition of ischemic contracture by nisoldipine seem to play a crucial role in improving myocardial dysfunction of ischemic-reperfused hearts.

Citing Articles

Effects of salvianolic acid B on L-type calcium channels and myocardial contractility in isolated rat ventricular myocytes and hERG K channels expressed in HEK293 cells.

Song Q, Han X, Xue Y, Song T, Chu X, Zhang X Naunyn Schmiedebergs Arch Pharmacol. 2017; 390(8):791-799.

PMID: 28477086 DOI: 10.1007/s00210-017-1381-4.

References

Steenbergen C, Murphy E, Watts J, London R . Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart. Circ Res. 1990; 66(1):135-46. DOI: 10.1161/01.res.66.1.135. View

Kihara Y, Grossman W, Morgan J . Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart. Circ Res. 1989; 65(4):1029-44. DOI: 10.1161/01.res.65.4.1029. View

Watts J, Whipple J, Hatley A . A low concentration of nisoldipine reduces ischemic heart injury: enhanced reflow and recovery of contractile function without energy preservation during ischemia. J Mol Cell Cardiol. 1987; 19(8):809-16. DOI: 10.1016/s0022-2828(87)80391-7. View

Gavin J, Humphrey S, Herdson P . The no-reflow phenomenon in ischemic myocardium. Int Rev Exp Pathol. 1983; 25:361-83. View

Kazda S, Garthoff B, Meyer H, SCHLOSSMANN K, STOEPEL K, Towart R . Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552). Arzneimittelforschung. 1980; 30(12):2144-62. View

de Jong J . Timely administration of nisoldipine essential for prevention of myocardial ATP catabolism. Eur J Pharmacol. 1985; 118(1-2):53-9. DOI: 10.1016/0014-2999(85)90662-4. View

Tumas J, Deth R, Kloner R . Effects of nisoldipine, a new calcium antagonist, on myocardial infarct size and cardiac dynamics following acute myocardial infarction. J Cardiovasc Pharmacol. 1985; 7(2):361-7. DOI: 10.1097/00005344-198503000-00023. View

de Jong J, Huizer T . Reduced glycolysis by nisoldipine treatment of ischemic heart. J Cardiovasc Pharmacol. 1985; 7(3):497-500. DOI: 10.1097/00005344-198505000-00013. View

Kern M . Influence of calcium channel antagonist therapy on the ischemic response to acute coronary occlusion in humans. Clin Cardiol. 1989; 12(7 Suppl 3):III77-85. View

10.

Duncker D, van Woerkens L, Serruys P, Roelandt J, Hugenholtz P, Verdouw P . Actions of nisoldipine in cardiovascular disease. Can J Cardiol. 1989; 5(5):266-74. View

11.

Umeda M, Saida K . Improvement of ischemic myocardial dysfunction by nisoldipine in relation to its coronary vasodilating action. Jpn J Pharmacol. 1993; 62(1):1-7. DOI: 10.1254/jjp.62.1. View

12.

Grover G, Dzwonczyk S, Sleph P . Comparative anti-ischemic effects of dihydropyridine calcium antagonists in isolated perfused rat hearts: relationship of cardiodepression and cardioprotection. Pharmacology. 1990; 40(3):137-49. DOI: 10.1159/000138652. View

13.

Watts J, Hawes E, JENKINS S, Williams T . Effects of nisoldipine on the no-reflow phenomenon in globally ischemic rat hearts. J Cardiovasc Pharmacol. 1990; 16(3):487-94. DOI: 10.1097/00005344-199009000-00020. View

14.

Kimball B, Watson K, Bui S, Frankel D . Preservation of left ventricular performance with reduced ischemic dysfunction by intravenous nisoldipine. Am J Cardiol. 1990; 66(4):400-5. DOI: 10.1016/0002-9149(90)90693-u. View

15.

Takayasu T, Toyo-oka T, Hosoda S . Waste of ATP for tension development in myocardial acidosis: chemomechanical uncoupling at myofibrillar level. J Mol Cell Cardiol. 1990; 22(2):127-30. DOI: 10.1016/0022-2828(90)91109-k. View

16.

Tzivoni D, Banai S, Botvin S, Zilberman A, WEISS T, Gavish A . Effects of nisoldipine on myocardial ischemia during exercise and during daily activity. Am J Cardiol. 1991; 67(7):559-64. DOI: 10.1016/0002-9149(91)90891-n. View

17.

Lahiri A, Rodrigues E, Carboni G, Raftery E . Effects of long-term treatment with calcium antagonists on left ventricular diastolic function in stable angina and heart failure. Circulation. 1990; 81(2 Suppl):III130-8. View

18.

Vandenberg J, Metcalfe J, Grace A . Mechanisms of pHi recovery after global ischemia in the perfused heart. Circ Res. 1993; 72(5):993-1003. DOI: 10.1161/01.res.72.5.993. View

19.

Sassen L, Bezstarosti K, Verdouw P, Lamers J . Effects of nisoldipine on recovery of coronary blood flow, sarcoplasmic reticulum function and other biochemical parameters in post-ischaemic porcine myocardium. Biochem Pharmacol. 1991; 41(1):43-51. DOI: 10.1016/0006-2952(91)90009-t. View

20.

Tilton R, Watts J, Land M, Larson K, Sutera S, Williamson J . Discordant effects of nisoldipine on coronary vascular resistance and permeability changes during reflow after ischemia in isolated rabbit hearts. J Mol Cell Cardiol. 1991; 23(7):861-72. DOI: 10.1016/0022-2828(91)90219-c. View